Literature DB >> 27056435

Prostate cancer radiation therapy: A physician's perspective.

Alan Dal Pra1, Luis Souhami2.   

Abstract

Prostate cancer is the second most common cancer in men and a major cause of cancer deaths worldwide. Ionizing radiation has played a substantial role in the curative treatment of this disease. The historical evolution of radiotherapy techniques through 3D-conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT) has allowed more accurate and precise treatments toward significant improvements in the therapeutic ratio. The addition of androgen deprivation therapy has significantly improved overall survival becoming the standard therapy for intermediate- and high-risk disease. Many randomized controlled trials have shown improved local control with dose escalation, and hypofractionated RT has been consolidated with proven efficacy and safe clinical results. However, several questions remain open in the radiotherapeutic management of prostate cancer patients and hopefully ongoing studies will shed light on these uncertainties. More individualized approaches are essential through better prognostic and novel predictive biomarkers of prostate radiotherapy response. Clinicians should critically interpret the evolving technologies in prostate cancer radiotherapy with important optimism but balancing the costs and the actual magnitude of clinical benefit. This article provides an overview of the basic aspects of radiotherapy treatment in localized prostate cancer from a physician's perspective.
Copyright © 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3-D radiotherapy; IMRT; Image-guided radiotherapy; Prostate cancer; Radiotherapy

Mesh:

Substances:

Year:  2016        PMID: 27056435     DOI: 10.1016/j.ejmp.2016.02.012

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  5 in total

Review 1.  Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Emile N van Lin; Joep G H van Roermund; Philippe Lambin
Journal:  Biomed Res Int       Date:  2016-12-28       Impact factor: 3.411

2.  Evaluation of a commercial DIR platform for contour propagation in prostate cancer patients treated with IMRT/VMAT.

Authors:  Jacob E Hammers; Sara Pirozzi; Daniel Lindsay; Orit Kaidar-Person; Xianming Tan; Ronald C Chen; Shiva K Das; Panayiotis Mavroidis
Journal:  J Appl Clin Med Phys       Date:  2020-02       Impact factor: 2.102

Review 3.  Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles.

Authors:  Ines Stevic; Gustav Buescher; Franz Lennard Ricklefs
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600

4.  Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy.

Authors:  Bijaya Malla; Daniel M Aebersold; Alan Dal Pra
Journal:  J Transl Med       Date:  2018-08-13       Impact factor: 5.531

5.  Intensity-Modulated Radiotherapy with Regional Hyperthermia for High-Risk Localized Prostate Carcinoma.

Authors:  Sota Nakahara; Takayuki Ohguri; Sho Kakinouchi; Hirohide Itamura; Takahiro Morisaki; Subaru Tani; Katuya Yahara; Naohiro Fujimoto
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.